Accuray to Showcase Advancements in Technology at ESTRO

Accuray Incorporated will showcase advances in hardware and software designed to improve the cancer treatment experience at the European Society for Radiotherapy and Oncology's (ESTRO) annual meeting, May 3 to May 7, 2024, in Glasgow, Scotland.

"This year's ESTRO meeting is particularly meaningful as we recognize –and celebrate – 30 years of collaborating with healthcare professionals and industry partners to develop ground-breaking technologies that expand the application of radiation therapy and access to patients who may benefit from care. The precision and accuracy of the CyberKnife and Radixact Systems enable our customers to personalize the way cancer is managed for each patient throughout their treatment journey while also treating more patients, better and faster, than ever before," said Suzanne Winter, president and CEO of Accuray.

The company will show CyberComm, a new physics offering intended to significantly reduce the CyberKnife S7 System's commissioning time and enable customers to begin treating patients significantly faster.

Cenos, a work-in-progress technology not currently cleared for clinical use, is designed to provide customers with the ability to perform online adaptation of their treatment plan to account for changes that may occur between treatment sessions. This latest innovation from Accuray for the Radixact System is intended to enable clinical teams to adapt on-demand based on the needs of the patient, ensuring clinical objectives are met while providing flexibility to optimize and streamline adaptive workflows.

"Accuray takes pride in our legacy of breakthroughs in cancer and neuro-radiosurgical technology. The CyberKnife System was the first platform to integrate robotic mobility with real-time imaging to address tumor motion, allowing unparalleled precision without the requirement of uncomfortable stereotactic frames," said Seth Blacksburg, M.D., MBA, Chief Medical Officer at Accuray. "With the TomoTherapy System—the precursor to the Radixact System—we furthered our impact by being the first to merge computed tomography (CT) with intensity-modulated radiation therapy (IMRT) within one system, enabling clinicians to deliver targeted helical radiation therapy designed to meticulously match the tumor's complex shape."

Continued Dr Blacksburg, "These innovations enable medical care teams worldwide to confidently and non-invasively treat a wide assortment of malignant and benign disease while minimizing the effect on healthy tissues. Our collaboration with world class physicians and engineers continues to forge improvements in oncology and neuro-radiosurgery, empowering the development of novel solutions that advance—and personalize—patient care."